We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genome-Wide Expression Analysis Helps Understand Leukemia Development

By LabMedica International staff writers
Posted on 19 Feb 2009
Print article
A genome-wide expression analysis compared highly enriched normal blood stem cells and leukemic stem cells, and identified several new pathways that have a key role in cancer development.

Using modern microarray technology, scientists revealed a string of stem-cell pathways; some were already well known and others not previously implicated in leukemia and other cancers. The scientists identified Three thousand and five differentially expressed genes. Among them, a ribosome and T-cell receptor signaling pathway emerged as having a role in regulation of the cancer stem cells.

The direct comparison of leukemic stems cells (obtained by consent from patients) to normal blood stem cells, provided critical insight into the differences found in malignancy that could be used to develop targeted therapy, said Michael W. Becker, M.D., an assistant professor at the James P. Wilmot Cancer Center at the University of Rochester Medical Center (URMC; Rochester, NY, USA). Professor Becker led the genome-wide expression study, which was described in the February 9, 2009 issue of the Proceedings of the [U.S.] National Academy of Sciences (PNAS).

Scientists believe the best way to eradicate cancer could be to find therapies that target cancer's stem cells--the cells thought to be responsible for maintaining the disease. Most cancer treatments today fail to attack cancer at its root, which is why the disease can recur despite aggressive therapy.

Related Links:

University of Rochester Medical Center



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.